Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's disease.

Autor: Kac PR; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden., Alcolea D; Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain., Montoliu-Gaya L; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden., Fernández S; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain., Rodriguez JL; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden., Maure L; Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain., González-Ortiz F; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Benejam B; Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain., Turton M; Bioventix Plc, Farnham, GU9 7SX, United Kingdom., Barroeta I; Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain., Harrison P; Bioventix Plc, Farnham, GU9 7SX, United Kingdom., Videla L; Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain., Ashton NJ; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, United Kingdom.; Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, London, United Kingdom., Lleó A; Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain., Zetterberg H; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.; UK Dementia Research Institute at UCL, London, United Kingdom., Carmona-Iragui M; Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain., Karikari TK; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Fortea J; Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain., Blennow K; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P.R. China.

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2024 Nov 02. Date of Electronic Publication: 2024 Nov 02.

Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease.

Autor: Gonzalez-Ortiz F; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. Fernando.gonzalez.ortiz@gu.se.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. Fernando.gonzalez.ortiz@gu.se., Kirsebom BE; Department of Neurology, University Hospital of North Norway, Tromsø, Norway.; Department of Psychology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway.; Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway., Contador J; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.; Hospital del Mar Research Institute, Barcelona, Spain.; Cognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain., Tanley JE; Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Selnes P; Department of Neurology, Akershus University Hospital, Lørenskog, Norway., Gísladóttir B; Department of Neurology, Akershus University Hospital, Lørenskog, Norway., Pålhaugen L; Department of Neurology, Akershus University Hospital, Lørenskog, Norway., Suhr Hemminghyth M; Research Group for Age-Related Medicine, Haugesund Hospital, Haugesund, Norway.; Department of Neuropsychology, Haugesund Hospital, Haugesund, Norway.; Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway., Jarholm J; Department of Neurology, Akershus University Hospital, Lørenskog, Norway., Skogseth R; Department of Geriatric Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.; Department of Clinical Sciences, Faculty of Medicine, University of Bergen, Bergen, Norway., Bråthen G; Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway.; Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Grøndtvedt G; Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway.; Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Bjørnerud A; Department of Physics, University of Oslo, Oslo, Norway.; Unit for Computational Radiology and Artificial Intelligence, Oslo University hospital, Oslo, Norway.; Department of Psychology, Faculty for Social Sciences, University of Oslo, Oslo, Norway., Tecelao S; Department of Neurology, Akershus University Hospital, Lørenskog, Norway., Waterloo K; Department of Neurology, University Hospital of North Norway, Tromsø, Norway.; Department of Psychology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway., Aarsland D; Department of Old Age Psychiatry. Institute of psychiatry, Psychology and Neuroscience King's College London, London, UK.; Centre for Age-Related Diseases, University Hospital Stavanger, Stavanger, Norway., Fernández-Lebrero A; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.; Hospital del Mar Research Institute, Barcelona, Spain.; Cognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, 08003, Spain.; ERA-Net on Cardiovascular Diseases (ERA-CVD) consortium, Barcelona, Spain., García-Escobar G; Hospital del Mar Research Institute, Barcelona, Spain.; ERA-Net on Cardiovascular Diseases (ERA-CVD) consortium, Barcelona, Spain., Navalpotro-Gómez I; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.; Hospital del Mar Research Institute, Barcelona, Spain.; Cognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.; ERA-Net on Cardiovascular Diseases (ERA-CVD) consortium, Barcelona, Spain., Turton M; Bioventix Plc, 7 Romans Business Park, East Street, Farnham, Surrey, GU9 7SX, UK., Hesthamar A; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Kac PR; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Nilsson J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Luchsinger J; Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Hayden KM; Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Harrison P; Bioventix Plc, 7 Romans Business Park, East Street, Farnham, Surrey, GU9 7SX, UK., Puig-Pijoan A; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.; Hospital del Mar Research Institute, Barcelona, Spain.; ERA-Net on Cardiovascular Diseases (ERA-CVD) consortium, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.; UK Dementia Research Institute at UCL, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA., Hughes TM; Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Suárez-Calvet M; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.; Hospital del Mar Research Institute, Barcelona, Spain.; Cognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain., Karikari TK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA., Fladby T; Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway.; Department of Neurology, Akershus University Hospital, Lørenskog, Norway., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Publikováno v: Nature communications [Nat Commun] 2024 Apr 04; Vol. 15 (1), pp. 2908. Date of Electronic Publication: 2024 Apr 04.

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.

Autor: Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; The George Institute for Global Health, Sydney, New South Wales, Australia., Greasley PJ; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ahlström C; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Althage M; Translational Science & Experimental Medicine, Research and Early Development Cardiovascular, Renal, and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gaithersburg, MD, USA., Dwyer JP; Division of Nephrology/Hypertension, University of Utah Health, Salt Lake City, UT, USA., Law G; Early Biometrics & Statistical Innovation, Data Science and Artificial Intelligence, R&D, AstraZeneca, Gaithersburg, MD, USA., Wijkmark E; Biometrics Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Lin M; Biometrics Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Mercier AK; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Sunnåker M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Turton M; Biopharma Clinical Operations, Early CVRM, AstraZeneca, Cambridge, UK., Wheeler DC; Department of Renal Medicine, University College London, London, UK., Ambery P; Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Publikováno v: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2024 Feb 28; Vol. 39 (3), pp. 414-425.

Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.

Autor: Gonzalez-Ortiz F; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Karikari TK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, Mölndal, Sweden.; Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Bentivenga GM; Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy., Baiardi S; Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy., Mammana A; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy., Turton M; Bioventix Plc, Farnham, Surrey, UK., Kac PR; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, Mölndal, Sweden., Mastrangelo A; Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy., Harrison P; Bioventix Plc, Farnham, Surrey, UK., Capellari S; Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.; UK Dementia Research Institute at UCL, Queen Square, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Science Park, Hong Kong, China.; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Parchi P; Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Publikováno v: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Jan; Vol. 20 (1), pp. 745-751. Date of Electronic Publication: 2023 Oct 19.

A novel ultrasensitive assay for plasma p-tau217: performance in individuals with subjective cognitive decline and early Alzheimer's disease.

Autor: Gonzalez-Ortiz F, Ferreira PCL, Gonzalez A, Montoliu-Gaya L, Ortiz-Romero P, Kac PR, Turton M, Kvartsberg H, Ashton NJ, Zetterberg H, Harrison P, Bellaver B, Povala G, Villemagne VL, Pascoal TA, Ganguli M, Cohen AD, Miguillon C, Contador J, Suarez-Calvet M, Karikari TK, Blennow K

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2023 Oct 05. Date of Electronic Publication: 2023 Oct 05.